Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor.
Antineoplastic Agents
/ administration & dosage
Bortezomib
/ administration & dosage
Brain Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
/ methods
Drug Synergism
Drug Therapy, Combination
Humans
Panobinostat
/ administration & dosage
Prognosis
Proteasome Inhibitors
/ administration & dosage
Rhabdoid Tumor
/ drug therapy
Teratoma
/ drug therapy
Atypical teratoid/rhabdoid tumor
Bortezomib
Drug screening
Panobinostat
Patient-derived cell line
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
01
06
2020
accepted:
17
09
2020
pubmed:
1
10
2020
medline:
2
7
2021
entrez:
30
9
2020
Statut:
ppublish
Résumé
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare intracranial tumor occurring predominantly in young children. The prognosis is poor, and no effective treatment is currently available. To develop novel effective therapies, there is a need for experimental models for AT/RT. In this research, we established a cell line from a patient's AT/RT tissue (designated ATRT_OCGH) and performed drug screening using 164 FDA-approved anti-cancer agents, to identify candidates for therapeutic options. We found that bortezomib, a proteasome inhibitor, was among the agents for which the cell line showed high sensitivity, along with tyrosine kinase inhibitors, topoisomerase inhibitors, and histone deacetylase inhibitors, which are known to exert anti-AT/RT effects. Concomitant use of panobinostat potentiated the inhibitory effect of bortezomib on AT/RT cell proliferation. Our findings may provide a rationale for considering combination therapy of panobinostat and bortezomib for treatment of AT/RT.
Identifiants
pubmed: 32997328
doi: 10.1007/s13577-020-00438-3
pii: 10.1007/s13577-020-00438-3
doi:
Substances chimiques
Antineoplastic Agents
0
Proteasome Inhibitors
0
Bortezomib
69G8BD63PP
Panobinostat
9647FM7Y3Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-278Références
Fruhwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro-oncology. 2016;18:764–78.
doi: 10.1093/neuonc/nov264
Richardson EA, Ho B, Huang A. Atypical teratoid rhabdoid tumour: from tumours to therapies. J Korean Neurosurg Soc. 2018;61:302–11.
doi: 10.3340/jkns.2018.0061
Yamasaki K, Kiyotani C, Terashima K, et al. Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Children’s Cancer Group. J Neurosurg Pediatr. 2019;25:1–10.
Torchia J, Golbourn B, Feng S, et al. Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell. 2016;30:891–908.
doi: 10.1016/j.ccell.2016.11.003
Johann PD, Erkek S, Zapatka M, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell. 2016;29:379–93.
doi: 10.1016/j.ccell.2016.02.001
Narendran A, Coppes L, Jayanthan A, et al. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J Neuro-Oncol. 2008;90:171–80.
doi: 10.1007/s11060-008-9653-y
Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2020;33:877.
doi: 10.1007/s13577-020-00354-6
Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.
doi: 10.7171/jbt.18-2902-002
Moreau P. How I treat myeloma with new agents. Blood. 2017;130:1507–13.
doi: 10.1182/blood-2017-05-743203
San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.
doi: 10.1016/S1470-2045(14)70440-1
Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–6.
pubmed: 11306489
Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–60.
doi: 10.1038/nrc1361
Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–69.
doi: 10.1200/JCO.2015.63.5904
Carugo A, Minelli R, Sapio L, et al. p53 is a aster regulator of proteostasis in SMARCB1-efficient malignant rhabdoid tumors. Cancer Cell. 2019;35:204–20.
doi: 10.1016/j.ccell.2019.01.006
Wu DY, Tkachuck DC, Roberson RS, Schubach WH. The human SNF5/INI1 protein facilitates the function of the growth arrest and DNA damage-inducible protein (GADD34) and modulates GADD34-bound protein phosphatase-1 activity. J Biol Chem. 2002;277:27706–15.
doi: 10.1074/jbc.M200955200
Hertwig F, Meyer K, Braun S, et al. Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells. Cancer Res. 2012;72:3381–92.
doi: 10.1158/0008-5472.CAN-11-3525
Pakos-Zebrucka K, Koryga I, Mnich K, et al. The integrated stress response. EMBO Rep. 2016;17:1374–95.
doi: 10.15252/embr.201642195
Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 2009;69:1545–52.
doi: 10.1158/0008-5472.CAN-08-3858
Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011;35:e47–e63.
doi: 10.1097/PAS.0b013e31822b325b
Carden MA, Smith S, Meany H, et al. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: two cases. Pediatr Blood Cancer. 2017;64:e26402.
doi: 10.1002/pbc.26402
Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 2006;24:e14.
doi: 10.1200/JCO.2005.05.0344
Raizer JJ, Chandler JP, Ferrarese R, et al. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J Neuro-Oncol. 2016;129:139–46.
doi: 10.1007/s11060-016-2156-3
Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10:2034–42.
doi: 10.1158/1535-7163.MCT-11-0433
Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727–38.
doi: 10.1016/S0092-8674(03)00939-5
Moreno N, Kerl K. Preclinical evaluation of combined targeted approaches in malignant rhabdoid tumors. Anticancer Res. 2016;36:3883–7.
pubmed: 27466490
Jochems J, Boulden J, Lee BG, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014;39:389–400.
doi: 10.1038/npp.2013.207